Multidomain lifestyle interventions combined with pharmacological or nutraceutical approaches may improve cognition in individuals across the Alzheimer's disease continuum.
A systematic review of 12 randomized controlled trials found that combining multidomain lifestyle interventions (2-7 domains including physical exercise, cognitive training, dietary guidance, social activities, sleep hygiene, cardiovascular/metabolic risk management, psychoeducation or stress management) with pharmacological components (e.g., Omega-3, Tramiprosate, vitamin D, BBH-1001, epigallocatechin gallate, Souvenaid, metformin) may effectively improve cognition. Seven trials targeted participants with prodromal AD, MCI, or early dementia, while five focused on at-risk individuals or those with subjective cognitive decline, with two studies enriching populations for APOE-ε4 carriers.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Multidomain lifestyle interventions combined with pharmacological or nutraceutical approaches may improve cognition in individuals across the Alzheimer's disease continuum. The current body of evidence comprises 1 study, including 1 randomized controlled trial. EvidenceHub rates the overall confidence at 42/100 (low).
The Claim
Multidomain lifestyle interventions combined with pharmacological or nutraceutical approaches may improve cognition in individuals across the Alzheimer's disease continuum.
This conclusion is most relevant to: Individuals across the Alzheimer's disease continuum, including cognitively normal at-risk individuals, those with subjective cognitive decline, mild cognitive impairment, or prodromal AD..
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Risk reduction and precision prevention across the Alzheimer's disease continuum: a systematic review of clinical trials combining multidomain lifestyle interventions and pharmacological or nutraceutical approaches. (The journal of prevention of Alzheimer's disease, 2025) —
How It Works
The proposed biological pathway:
- ▸Multidomain lifestyle interventions target multiple risk factors and disease mechanisms
- ▸Pharmacological components add complementary effects
- ▸Tailored and early implementation optimizes intervention timing
- ▸Result: Potential improvement in cognition
Who Might Benefit
Evidence fit by population:
- ▸Individuals across the Alzheimer's disease continuum, including cognitively normal at-risk individuals, those with subjective cognitive decline, mild cognitive impairment, or prodromal AD.
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Only 12 RCTs were identified, limiting generalizability
- ▸Further refinement of RCT methodology is needed to better align with the multifaceted nature of dementia prevention
Frequently Asked Questions
What types of lifestyle domains were included in the interventions?▼
The interventions included 2 to 7 lifestyle domains such as physical exercise, cognitive training, dietary guidance, social activities, sleep hygiene, cardiovascular/metabolic risk management, and psychoeducation or stress management.
Which pharmacological components were combined with lifestyle interventions?▼
Pharmacological components included Omega-3, Tramiprosate, vitamin D, BBH-1001, epigallocatechin gallate, Souvenaid, and metformin.
Who was the target population for these combination trials?▼
The target population included individuals across the Alzheimer's disease continuum: cognitively normal at-risk individuals, those with subjective cognitive decline, mild cognitive impairment, or prodromal AD.
What was the minimum duration of the interventions in the reviewed trials?▼
All included interventions lasted at least 6 months.
References
- 1.Bereczki E, Mangialasche F, Barbera M, Padilla P, Hara Y, Fillit H, Solomon A, Kivipelto M. “Risk reduction and precision prevention across the Alzheimer's disease continuum: a systematic review of clinical trials combining multidomain lifestyle interventions and pharmacological or nutraceutical approaches..” The journal of prevention of Alzheimer's disease, 2025. PMID: 41145344 DOI: 10.1016/j.tjpad.2025.100367